Peripheral blood progenitor cell transplantation: economic issues

Area of Science:

• Oncology
• Health Economics

Background:

• High-dose chemotherapy with autologous hematopoietic stem cell rescue is a costly cancer treatment.
• While offering improved long-term survival, its economic viability is increasingly scrutinized.
• The cost-effectiveness is closely tied to the survival advantage over standard-dose chemotherapy.

Purpose of the Study:

• To evaluate the cost-effectiveness of high-dose chemotherapy with autologous hematopoietic stem cell rescue.
• To review economic analyses concerning this treatment modality, particularly in breast cancer.
• To identify strategies aimed at reducing the overall cost of this intensive therapy.

Main Methods:

• Economic analyses and cost-effectiveness ratio assessments were reviewed.
• Comparisons were made between high-dose and standard-dose chemotherapy outcomes.
• Investigated cost-reduction strategies were identified.

Main Results:

• The cost-effectiveness ratio for high-dose chemotherapy in breast cancer treatment is comparable to other accepted medical interventions.
• Survival benefit is the primary determinant of its cost-effectiveness.
• Various centers are exploring methods to decrease therapy expenses.

Conclusions:

• High-dose chemotherapy with autologous hematopoietic stem cell rescue presents a complex cost-benefit profile.
• Further research into cost-reduction strategies is crucial for wider application.
• Optimizing treatment delivery and resource utilization can enhance economic feasibility.